Therefore, it is used in cancers with PIK3CA mutations, in particular uterine serous carcinomas and breast cancers, which are accompanied by hormone receptor changes because of the cross-talk between estrogen receptor (ER) and PI3K (141). Here, PIK3CA is linked to endometrial serous adenocarcinoma.